Alnylam Pharmaceuticals
Created in 2002
Up & running (A)
Existing signals show a regular activitySocial networks
13,519 16,470 222,675Entity types
Location
675 W Kendall St, Cambridge, MA 02142, USA
Cambridge
United States of America
Employees
Scale: 1001-5000
Estimated: 2,459
Engaged catalyst
34
0 0Added in Motherbase
4 years, 2 months ago
Value proposition
Alnylam is the leading RNAi therapeutics company. We're a fast-growing biopharma with a deep pipeline and global reach.
SILENCE DISEASE. AMPLIFY LIFE.TM
Alnylam is a leading independent biopharmaceutical company and the pioneer in RNA interference (RNAi) therapeutics – a revolutionary approach to treating diseases which “silences” the genes that cause or contribute to them.
Founded in 2002 by a group of distinguished researchers and biotech leaders, Alnylam’s work over more than two decades has yielded the critical breakthroughs and advancements that have made the field of (RNAi) therapeutics possible. In 2018, our first commercial medicine, and the world’s first RNAi therapeutic was approved. Since then, four more Alnylam-developed medicines have been approved and we’re hard at work developing new therapies to treat both rare and prevalent diseases.
We are a global and diverse company of 2,500+ people. We pride ourselves on fostering a fun, inclusive and dynamic work environment where employees can recognize their fullest potential. That's why we’re consistently ranked as a top employer by The Boston Globe (2015-24), Science Magazine (2018-24), Fast Company (Best Workplaces for Innovators 2020-24) and LinkedIn (2024).
We are based in Cambridge, Massachusetts (U.S.), with offices throughout North America, Europe, Asia, and South America.
See our social media community guidelines: https://bit.ly/2FcRhJy.
Please note: If you wish to report an adverse event or product complaint, please email medinfo@alnylam.com or you may call us using the following telephone numbers: for North America, 877.ALNYLAM (877.256.9526), for Europe, +31 20 369 7861
Biotech, Pharmaceuticals, Biopharma, Drug Development, Rare Diseases, and RNAi
Alnylam® Pharmaceuticals
Learn about Alnylam Pharmaceuticals, RNAi therapeutics, and the company's efforts in treating amyloidosis, hyperoxaluria, and porphyria.
https://www.alnylam.com/
| Catalyst | Type | Tweets | Articles | |
|---|---|---|---|---|
 SGInnovate Venture Capital and Private Equity Principals | SGInnovate Venture Capital and Private Equity Principals | Other 6 Feb 2023 | | |
 MSD Pharmaceutical, Pharmaceutical Manufacturing | MSD Pharmaceutical, Pharmaceutical Manufacturing | Other 15 May 2019 | | |
 STMicroelectronics Semiconductors, Semiconductor Manufacturing | STMicroelectronics Semiconductors, Semiconductor Manufacturing | Other 19 Jun 2020 | | |
 Illumina For Startups Startup accelerator & VC, Biotechnology, Biotechnology Research | Illumina For Startups Startup accelerator & VC, Biotechnology, Biotechnology Research | Other 26 Jun 2015 | | |
 Oxford Science Enterprises Startup accelerator & VC, Venture Capital and Private Equity Principals | Oxford Science Enterprises Startup accelerator & VC, Venture Capital and Private Equity Principals | Other 1 Mar 2022 | | |
 Teva Pharmaceuticals Pharmaceutical, Pharmaceutical Manufacturing | Teva Pharmaceuticals Pharmaceutical, Pharmaceutical Manufacturing | Other 24 Jun 2021 | | |
 FirstWord Pharma Pharmaceutical, Pharmaceutical Manufacturing | FirstWord Pharma Pharmaceutical, Pharmaceutical Manufacturing | Other 16 Aug 2022 | | |
 AstraZeneca Pharmaceutical, Pharmaceutical Manufacturing | AstraZeneca Pharmaceutical, Pharmaceutical Manufacturing | Other 22 Mar 2022 | | |
 Boehringer Ingelheim Pharmaceutical, Pharmaceutical Manufacturing, Animal Health | Boehringer Ingelheim Pharmaceutical, Pharmaceutical Manufacturing, Animal Health | Other 23 Jul 2019 | | |
 Fresenius Medical Care Pharmaceutical, Hospitals and Health Care | Fresenius Medical Care Pharmaceutical, Hospitals and Health Care | Other 22 Oct 2020 | | |
For Rare Disease Day, we asked members of the acute hepatic #porphyria (AHP) community to share their dreams for the future of rare disease.
Katri, who lives with AHP, wishes for happiness and stability. See her dream brought to life through generative AI to depict a world that is “More Than You Can Imagine.” #RareDiseaseDay
EURORDIS-Rare Diseases Europe
National Organization for Rare Disorders
Healthcare Professionals: People living with hereditary #ATTR (#hATTR) often experience significant and irreversible disease progression before an accurate diagnosis is made. In a new Alnylam-sponsored Healio article, Johanna Contreras, MD, MSc and Said Beydoun, MD, FAAN discuss the urgency to diagnose and manage this inherited #RareDisease. Learn more: https://bit.ly/4f9H9fu
#Amyloidois
For #RareDiseaseDay, we asked members of the #porphyria, #hyperoxaluria and #amyloidosis communities to share their dreams for the future of rare disease.
Rick, who lives with hereditary #ATTR (#hATTR) amyloidosis, dreams of celebrating his granddaughters' life milestones. See Rick's dream artistically transformed using generative AI to depict a world that is “More Than You Can Imagine.”
Rare Disease Day
EURORDIS-Rare Diseases Europe
National Organization for Rare Disorders
For U.S. Healthcare Professionals: Staying up to date on #RareDiseases like primary #hyperoxaluria type 1 (PH1) can help support patient care. Hear from pediatric nephrologist Dr. Stone as she discusses PH1 and an FDA-approved treatment option. https://bit.ly/3ZN7Ulq
HCPs: Conversations about family health history can help your patients understand inherited diseases, like hereditary #ATTR (#hATTR) #amyloidosis. Encourage your patients to discuss health conditions that run in their families to better understand their health. https://bit.ly/3QPohJd #hATTRoadTrip